Your session is about to expire
← Back to Search
Siremadlin + Venetoclax + Azacitidine for Acute Myeloid Leukemia
Study Summary
This trial is testing a new combination of drugs to treat AML in adults who are not eligible for chemotherapy.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My physical ability, blood cell count, liver, and kidney functions meet the study's requirements.I have been treated with FLT3 inhibitors.I need treatment with specific drugs that are sensitive to changes in their blood levels.I have AML and can't undergo standard chemotherapy due to my condition.I have previously been treated with MDM2-inhibitor therapy.I have a specific type of leukemia (AML-M3/APL) or AML because of Down's syndrome.My cancer has a TP53 mutation.I need to take certain medications for my condition.My cancer has a del17p genetic mutation.I am 18 years or older.I cannot receive standard intense chemotherapy due to my age or health conditions.
- Group 1: Arm 1: Unfit adult participants with AML who responded sub-optimally to standard of care
- Group 2: Arm 2: Newly diagnosed unfit adult participants with high-risk AML
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this clinical trial only testing for subjects under the age of 55?
"According to the eligibility requirements published for this trial, patients must be aged 18-99. There are 491 other trials available for patients that are under 18 and 1613 studies listed for patients over 65."
How many research facilities are handling this trial's data?
"Right now, there are 6 sites where this clinical trial is enrolling patients. They can be found in cities like Portland and Houston as well as Longmont and 6 other locations. If you want to take part in the study, try to choose a location that's close to minimize travel."
To your knowledge, what other research has been conducted with siremadlin?
"At present, 354 separate clinical trials are underway to study siremadlin. Of these, 55 are in Phase 3. While some of the trials for siremadlin are based in Edmonton, Alberta, there are 11349 locations running studies for siremadlin globally."
Are you looking for more participants in this research?
"Yes, this information can be found on the website clinicaltrials.gov. The study was created on 5/17/2022 and was last edited on 10/25/2022."
Siremadlin has been used for what indications most often?
"Siremadlin is a common induction chemotherapy medication, but it can also be used to treat other blood disorders like refractory anemias, leukemia, and myelocytic acute."
What are the goals that researchers are hoping to achieve with this clinical trial?
"The primary objective of this trial, which will be assessed over a period of 196 days, is to determine the percentage of participants with dose limiting toxicities. Secondary outcomes include the percentage of participants treated at the recommended expansionary dose who achieve complete remission and the proportion of participants achieving CR or complete remission with partial/incomplete hematological recovery. Additionally, the trial hopes to assess the effect of siremadlin in combination with venetoclax plus azacitidine on measurable residual disease."
Can I join this clinical trial?
"Myeloid leukemia patients that are between 18-99 years old qualify for this study, of which around 55 are needed."
Share this study with friends
Copy Link
Messenger